2-Acetamido-3-(3-methylimidazol-4-yl)propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Acetamido-3-(3-methylimidazol-4-yl)propanoic acid
• 化学式: C₉H₁₃N₃O₃
• 分子量: 211.22
• InChiKey: FKTXRTPBUWLETL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  84.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP3410115A1

  公开（公告）日：2018-12-05

  Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.

  本研究提供了肾功能生物标志物以及使用上述生物标志物评估肾功能、监测肾功能、诊断急性肾损伤和诊断慢性肾病的方法。此外，还提供了作为慢性肾病生物标志物的小分子实体套件。
• Methods of treating and diagnosing disease using biomarkers for BCG therapy
  申请人：The General Hospital Corporation

  公开号：US11266730B2

  公开（公告）日：2022-03-08

  The invention provides methods of treating disease, such as hypercholesterolemia (e.g., by modulating serum lipids, such as cholesterol, low-density lipoproteins, high-density lipoproteins, and triglycerides) and hyperglycemia by administering Bacillus Calmette-Guerin (BCG). Methods of the invention also encompass the use of genomic, proteomic, and metabolomic analyses for determining the likelihood that a patient has disease or will respond to treatment (e.g., with BCG therapy), as well as for determining whether a patient previously administered BCG would benefit from BCG redosing.

  本发明提供了治疗疾病的方法，例如高胆固醇血症（例如通过调节血清脂质，如胆固醇、低密度脂蛋白、高密度脂蛋白和甘油三酯）和通过施用卡介苗杆菌（BCG）治疗高血糖症。本发明的方法还包括使用基因组学、蛋白质组学和代谢组学分析来确定患者患病的可能性或对治疗（如卡介苗治疗）产生反应的可能性，以及确定先前施用卡介苗的患者是否会从卡介苗再给药中获益。
• BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP2997366B1

  公开（公告）日：2018-10-10
• METHODS OF TREATING AND DIAGNOSING DISEASE USING BIOMARKERS FOR BCG THERAPY
  申请人：The General Hospital Corporation

  公开号：EP3355914A1

  公开（公告）日：2018-08-08
• PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170276669A1

  公开（公告）日：2017-09-28

  The present invention relates to the field of nephrology. More specifically, the present invention provides methods and compositions useful for more precisely estimating glomerular filtration rate (GFR). In a specific embodiment, a method for calculating the estimated glomerular filtration rate (eGFR) in a patient comprises the steps of (a) measuring the level of one or more metabolites using mass spectrometry from a blood sample obtained from the patient; and (b) calculating the eGFR using an algorithm that utilizes the measured levels of the one or more metabolites.